Tiragolumab
An immune-brake blocker that looked excellent in a phase 2 lung cancer trial and then failed every phase 3.
CITYSCAPE (phase 2, 2020) showed tiragolumab plus atezolizumab roughly doubled response rate in PD-L1-high NSCLC. Phase 3 SKYSCRAPER-01 (PD-L1-high NSCLC) missed PFS and OS; SKYSCRAPER-02 (extensive-stage SCLC) was negative; SKYSCRAPER-06 (non-squamous NSCLC) was worse than control. Roche discontinued most of the programme in 2024–25. Other anti-TIGIT antibodies (domvanalimab, ociperlimab) showed no clearer benefit.
Lesson: a small randomised phase 2 with a surrogate endpoint in a selected population can mislead; redundancy between checkpoints means blocking a second one does not necessarily add to PD-1/PD-L1 blockade.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Tiragolumab" OR ABSTRACT:"Tiragolumab" OR TITLE:"RG6058" OR ABSTRACT:"RG6058" OR TITLE:"MTIG7192A" OR ABSTRACT:"MTIG7192A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tiragolumab, not a curated reading list.